H.C. Wainwright Raises Price Targets for LB Pharmaceuticals and Climb Bio

H.C. Wainwright has increased its price target for LB Pharmaceuticals to $60 and for Climb Bio to $24. These adjustments reflect the firm's updated outlook on the companies' stock valuations.